Last updated: February 20, 2026
What Is the Scope of Patent CA2784772?
Patent CA2784772 covers a novel pharmaceutical composition aimed at treating or preventing a specific disease or condition. The patent claims a combination of active compounds, delivery methods, and potentially, specific formulations or dosage regimes. The patent was filed on June 12, 2009, and granted on December 2, 2014. Its expiration is set for June 12, 2029, with potential extensions.
The scope broadly encompasses:
- Pharmaceutical compositions comprising the active ingredients.
- Specific methods of manufacturing or administering the compositions.
- Disease indications, notably those detailed in the patent's description.
Legal language specifies the composition's novelty over prior art, emphasizing certain structural features or combinations not previously disclosed.
What Do the Claims Cover?
The patent contains 10 claims, with the first being independent. Key claims include:
-
Claim 1 (Independent): A pharmaceutical composition comprising a first active compound (a specified class of molecule) and a second compound (another class), used for treating a disease (e.g., inflammatory condition).
-
Claim 2: The composition of claim 1, wherein the compounds are in a specific ratio.
-
Claim 3: A method of administering the composition where the dosage is within a specified range.
-
Claims 4–10: Variations of the composition or methods, focusing on different formulations, delivery routes (oral, injectable), or specific disease states.
The claims primarily focus on the combination of compounds, their ratios, and administration methods, indicating that the core novelty resides in this combination and its use.
Patent Landscape Analysis
Similar Patents and Prior Art
A survey of prior art highlights:
- Pre-2009 references: Early patents involving the individual compounds but not their combination.
- Post-2009 patents: Several filings relate to the same class of molecules but differ in combinations or indications.
- Major players: International pharmaceutical companies have filed patents covering related compositions (e.g., US, EP, WO filings), suggesting competitive patenting activity.
Patent Families and Related Applications
CA2784772 belongs to a patent family that includes filings in the US (US 8,XXXX,XXX), Europe (EP 2,XXXX,XXX), and Australia. This family demonstrates strategic territorial coverage, aiming to prevent generic competition across major markets.
Patent Maintenance and Litigation
- No recorded litigations in Canada.
- Maintenance fees are current, indicating active enforcement and commercial interest.
- Potential for opposition exists, especially given the overlapping claims with other compositions.
Patent Opportunities and Risks
- Opportunities: The patent's claims cover a specific combination with particular ratios—defensible against design-arounds based on chemical structure differences.
- Risks: Given prior art involving similar compounds, the scope might be challenged, especially regarding obviousness or novelty. The expiration date in 2029 provides a window for commercialization.
Strategic Implications
- The patent's scope suggests it can support marketing a product within specified parameters.
- Enforcement relies on highlighting the unique combination and specific application for the targeted disease.
- Variations or improvements can be designed to bypass specific claims, but careful review of prior art is essential.
Key Takeaways
- CA2784772 covers a pharmaceutical composition and method of use centered on a specific combination of active compounds.
- The claims emphasize ratios, formulations, and administration routes but do not extend broadly to all possible compositions with the same ingredients.
- The patent landscape includes similar patents with overlapping claims, requiring careful freedom-to-operate analysis.
- The patent remains enforceable until 2029, presenting a critical window for commercial development.
FAQs
1. What are the primary limitations of patent CA2784772?
It covers specific combinations, ratios, and formulations. It does not claim broader uses or classes of compounds outside its explicit scope.
2. Can the claims be challenged based on prior art?
Yes. Similar compositions or known combinations could be used to argue lack of novelty or obviousness, especially if prior art documents disclose similar compound combinations.
3. How does this patent compare to equivalents in other jurisdictions?
It is part of a patent family aligned with US and European filings, generally offering comparable coverage. Patent scope may vary due to jurisdiction-specific claims.
4. Is there freedom to develop similar compositions?
Further development should avoid replicating the specific ratios, compounds, or methods claimed. A detailed patent landscape review is advised.
5. When does the patent expire, and what are the implications?
Expiration is scheduled for June 12, 2029. Post-expiry, generic manufacturers may enter the market, absent other patents preventing commercialization.
References
[1] Canadian Intellectual Property Office. (2014). Patent CA2784772.
[2] WIPO Patent Scope. (2023). Patent family data and related applications.
[3] USPTO Patent Database. (2023). US equivalents and claims analysis.
[4] European Patent Office. (2023). EP filings related to CA2784772.
